Skip to content

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

TARS Tarsus Pharmaceuticals, Inc. Common Stock
$68.26 -3.93% -2.79
Notify me if price changes either direction
Interactive Brokers Logotype

Buy TARS stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades
Loading

Key Stats

Market cap. 2.9B
Enterprise value 2.7B
Trailing PE -22.26710117601
Forward PE 49.566677
PEG Ratio 0.43815908765698
Enterprise to EBITDA -31.49
Enterprise to revenue 7.364
Price to book MRQ 8.984038
Price to sales TTM 8.223137

Financials

Fiscal Year Ends 2024-12-31
Most Recent Quarter (MRQ) 2025-09-30
Revenue (TTM) 366.1M
EBITDA -85609000
Diluted EPS TTM -1.99
Total Cash (MRQ) 401.8M
Current ratio (MRQ) 4.286
Operating Cash Flow (TTM) -53963000

TARS trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent TARS News

Home

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.